Immunocore (IMCR) announces strategic priorities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
January 10, 2025 7:00 AM ESTÂ Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration
Enrolling three Phase 3 trials across multiple melanoma indications potential data readouts beginning with TEBE-AM in 2026
Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE)
Presenting initial HIV Phase 1 MAD data in the first quarter 2025
Progressing first-in-class, tissue-tethered autoimmune platform Type 1 diabetes candidate on track for CTA submission in 2025; first... More
